Associated Retina Consultants (ARC) will conduct two new clinical trials for the treatment of Stargardt disease and age-related macular degeneration. Stargardt disease is the most common childhood onset of macular dystrophy with central vision loss and age-related macular degeneration is the leading cause of vision loss among people age 50 or older.
The goal with the new treatment is to prevent progression of these retinal diseases. Using a technology called microperimetry, the physicians at ARC are able to evaluate small changes in the vision and are capable of assessing the patient’s needs and providing the highest level of care. The microperimetry measurements will enable ARC to implement clinical trials for the treatment of Stargardt disease and age-related macular degeneration.
“The generous donation of a microperimeter by the Sell foundation will allow us to offer the first clinical trial in Arizona for an inherited eye disease.” said Benjamin Bakall, MD, PhD, the director for the Inherited Retinal Dystrophy and Visual Function clinic at ARC. “We know that in Stargardt disease there is accumulation of toxic compounds that cause the degeneration of the retina and the treatment in this clinical trial is engineered to prevent the formation of these compounds. The same treatment will be used for age-related macular degeneration, which has a similar disease process. The microperimeter will enable us to evaluate and treat patients more effectively and will advance the treatment of Stargardt disease and dry age-related macular degeneration, for where there currently is no cure”.